Use of Serum Clara Cell 16-kDa (CC16) Levels as a Potential Indicator of Active Pulmonary Fibrosis in Systemic Sclerosis
Use of Serum Clara Cell 16-kDa (CC16) Levels as a Potential Indicator of Active Pulmonary Fibrosis in Systemic Sclerosis
复制标题
DOI：
10.3899/jrheum.100591
复制
发表时间：
2011-05-01
影响因子：
3.9
通讯作者：
Takehara, Kazuhiko
中科院分区：
文献类型：
--
作者：
Hasegawa, Minoru;Fujimoto, Manabu;Takehara, Kazuhiko
Objective.目的探讨血清Clara细胞16-kDa蛋白（CC 16;以前表示COO）浓度在系统性硬化症（SSc）患者肺纤维化（PF）诊断和监测中的临床意义;并将CC 16水平与目前最可靠的PF血清标志物如Krebs von den Lungen-6（KL-6）抗原和表面活性蛋白-D（SP-D）水平进行比较。采用酶联免疫吸附法（ELISA）检测了92例SSc患者、20例系统性红斑狼疮（SLE）患者和20例健康对照者血清CC 16、KL-6和SP-D水平。在一项回顾性纵向研究中，对16例SSc合并PF患者的血清CC 16水平与PF活性进行了相关性评估。虽然SSc患者的CC 16水平高于SLE患者或健康对照，但差异不显著。血清CC 16水平升高与PF，尤其是活动性PF，以及KL-6和SP-D的参与有关。受试者工作特征曲线分析显示，CC 16的效用略逊于KL-6，但与SP-D检测SSc患者PF的效用相当。在纵向研究中，与疾病活动期相比，疾病非活动期的血清CC 16、KL-6和SP-D水平显著降低。CC 16水平可用作SSc患者中PF和SP-D的潜在血清生物标志物。（2011年1月15日首次发布; J Rheumol 2011;38：877-84; doi：10.3899/jrheum.100591）
Objective. To clarify the clinical significance of concentrations of serum Clara cell 16-kDa protein (CC16; previously denoted COO) in the diagnosis and monitoring of pulmonary fibrosis (PF) in patients with systemic sclerosis (SSc); and to compare CC16 levels with levels of the current most reliable serum markers for PF, such as Krebs von den Lungen-6 (KL-6) antigen and surfactant protein-D (SP-D).Methods. Serum levels of CC16, KL-6, and SP-D were determined by ELISA in 92 patients with SSc, 20 patients with systemic lupus erythematosus (SLE), and 20 healthy controls. In a retrospective longitudinal study, correlation of serum CC16 levels with the activity of PF was assessed in 16 SSc patients with PF.Results. Although CC16 levels were higher in patients with SSc than in SLE patients or healthy controls, the difference was not significant. Increased serum CC16 levels were associated with involvement of PF, especially active PF, as well as KL-6 and SP-D. Receiver operating characteristic curve analysis revealed that the utility of CC16 is slightly inferior to KL-6, but was comparable with that of SP-D for detecting PF in patients with SSc. In the longitudinal study, serum levels of CC16,KL-6, and SP-D were significantly decreased in the inactive disease phase compared to the active disease phase.Conclusion. CC16 levels can be used as a potential serum biomarker for PF in addition to and SP-D in patients with SSc. (First Release Jan 15 2011; J Rheumatol 2011;38:877-84; doi:10.3899/jrheum.100591)